Honored to present the results of our MIMOSA-trial (monalizumab + trastuzumab for HER2+ MBC) at last weeks #SABCS22

Class of 2023 #MCCRWorkshop. Thanks to the organising partners EORTC-ESMO - Eur. Oncology-AACR

Excited to share the results of the MIMOSA-trial, in which we evaluated the novel combination of monalizumab & trastuzumab for HER2+ MBC! Thanks to the entire MIMOSA-team! MarleenKokLab sciencedirect.com/science/articl…

Patients with triple negative breast cancer and high immune cell (TILs) counts in their tumors have better survival rates even without chemotherapy. Study by MarleenKokLab highlights that these TILs are key in predicting recovery ➡️ nki.nl/news-events/ne… #BreastCancer #Research

Congrats Veerle Geurts and TILs Working Group. Why is this JAMA Oncology paper important? Its known that TILs are progn in TNBC and that not all stage I TNBC pts benefit from chemo.👇we show that pT1cN0 pts with high TILs have excel survival without chemo! The Netherlands Cancer Institute

Excited to present 🎤 first data #SABCS24 from TONIC2. Follow-up from nature.com/articles/s4159…. Are immune induction with dox or cisplatin indeed benefiting pts? Veerle Geurts at P1-7-30 and new data on acquired resist🔬 to aPD1 at PS17-09 The Netherlands Cancer Institute OncoAlert Nature Medicine